Literature DB >> 29016996

Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma.

Bogdana Suchorska1, Armin Giese1, Annamaria Biczok1, Marcus Unterrainer1, Michael Weller1, Mark Drexler1, Peter Bartenstein1, Ulrich Schüller1, Jörg-Christian Tonn1, Nathalie L Albert1.   

Abstract

Background: Stratification of glioma according to isocitrate dehydrogenase 1/2 (IDH1/2) mutation and 1p/19q codeletion status has gained major importance in the new World Health Organization (WHO) classification. Parameters derived from uptake dynamics of 18F-fluoro-ethyl-tyrosine PET (18F-FET-PET) such as minimal time-to-peak (TTPmin) allow discrimination between different prognostic glioma subgroups, too. The present study is aimed at exploring whether TTPmin analysis provides prognostic information beyond the WHO classification.
Methods: Three hundred patients with newly diagnosed WHO 2007 grades II-IV gliomas with 18F-FET-PET imaging at diagnosis were grouped into 4 subgroups (IDH1/2 mut-1p/19q codel; IDH1/2 mut-1p/19q non-codel; IDH1/2 wildtype WHO grade II and III tumors; and glioblastoma). Clinical and imaging factors such as age, Karnofsky performance score, treatment, TTPmin, and maximal tumor-to-brain ratio (TBRmax) were analyzed with regard to progression-free and overall survival (PFS and OS) via univariate and multivariate regression analysis.
Results: PFS and OS were longest in the IDH1/2 mut-1p/19q codel subgroup, followed by IDH1/2 mut-1p/19q non-codel, IDH1/2 wildtype, and GBM (P < 0.001). Further, outcome stratified by TTPmin with a cutoff of 17.5 minutes revealed significantly longer PFS and OS in patients with TTPmin >17.5 minutes (P < 0.001 for PFS and OS). Lower TBRmax values or the absence of 18F-FET uptake was also associated with favorable outcome in the entire group. In the subgroup analyses, longer median TTPmin was associated with improved outcome specifically in the IDH1/2 mut-1p/19q non-codel group.
Conclusion: 18F-FET-PET-derived dynamic analysis defines prognostically distinct subgroups of IDH1/2 mutant-1p/19q non-codel gliomas which cannot be distinguished as yet by molecular marker analysis.
© The Author(s) 2017. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  18F-FET-PET; 1p/19q co-deletion; IDH1/2 mutation; glioma; kinetic analysis; prognostic value

Mesh:

Substances:

Year:  2018        PMID: 29016996      PMCID: PMC5777500          DOI: 10.1093/neuonc/nox153

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  27 in total

Review 1.  O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications.

Authors:  Karl-Josef Langen; Kurt Hamacher; Matthias Weckesser; Frank Floeth; Gabriele Stoffels; Dagmar Bauer; Heinz H Coenen; Dirk Pauleit
Journal:  Nucl Med Biol       Date:  2006-04       Impact factor: 2.408

2.  MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Authors:  Nathalie L Jansen; Vera Graute; Lena Armbruster; Bogdana Suchorska; Juergen Lutz; Sabina Eigenbrod; Paul Cumming; Peter Bartenstein; Jörg-Christian Tonn; Friedrich Wilhelm Kreth; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-11       Impact factor: 9.236

3.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

4.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Authors:  Daniel J Brat; Roel G W Verhaak; Kenneth D Aldape; W K Alfred Yung; Sofie R Salama; Lee A D Cooper; Esther Rheinbay; C Ryan Miller; Mark Vitucci; Olena Morozova; A Gordon Robertson; Houtan Noushmehr; Peter W Laird; Andrew D Cherniack; Rehan Akbani; Jason T Huse; Giovanni Ciriello; Laila M Poisson; Jill S Barnholtz-Sloan; Mitchel S Berger; Cameron Brennan; Rivka R Colen; Howard Colman; Adam E Flanders; Caterina Giannini; Mia Grifford; Antonio Iavarone; Rajan Jain; Isaac Joseph; Jaegil Kim; Katayoon Kasaian; Tom Mikkelsen; Bradley A Murray; Brian Patrick O'Neill; Lior Pachter; Donald W Parsons; Carrie Sougnez; Erik P Sulman; Scott R Vandenberg; Erwin G Van Meir; Andreas von Deimling; Hailei Zhang; Daniel Crain; Kevin Lau; David Mallery; Scott Morris; Joseph Paulauskis; Robert Penny; Troy Shelton; Mark Sherman; Peggy Yena; Aaron Black; Jay Bowen; Katie Dicostanzo; Julie Gastier-Foster; Kristen M Leraas; Tara M Lichtenberg; Christopher R Pierson; Nilsa C Ramirez; Cynthia Taylor; Stephanie Weaver; Lisa Wise; Erik Zmuda; Tanja Davidsen; John A Demchok; Greg Eley; Martin L Ferguson; Carolyn M Hutter; Kenna R Mills Shaw; Bradley A Ozenberger; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean Claude Zenklusen; Brenda Ayala; Julien Baboud; Sudha Chudamani; Mark A Jensen; Jia Liu; Todd Pihl; Rohini Raman; Yunhu Wan; Ye Wu; Adrian Ally; J Todd Auman; Miruna Balasundaram; Saianand Balu; Stephen B Baylin; Rameen Beroukhim; Moiz S Bootwalla; Reanne Bowlby; Christopher A Bristow; Denise Brooks; Yaron Butterfield; Rebecca Carlsen; Scott Carter; Lynda Chin; Andy Chu; Eric Chuah; Kristian Cibulskis; Amanda Clarke; Simon G Coetzee; Noreen Dhalla; Tim Fennell; Sheila Fisher; Stacey Gabriel; Gad Getz; Richard Gibbs; Ranabir Guin; Angela Hadjipanayis; D Neil Hayes; Toshinori Hinoue; Katherine Hoadley; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven Jones; Corbin D Jones; Raju Kucherlapati; Phillip H Lai; Eric Lander; Semin Lee; Lee Lichtenstein; Yussanne Ma; Dennis T Maglinte; Harshad S Mahadeshwar; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew L Meyerson; Piotr A Mieczkowski; Richard A Moore; Lisle E Mose; Andrew J Mungall; Angeliki Pantazi; Michael Parfenov; Peter J Park; Joel S Parker; Charles M Perou; Alexei Protopopov; Xiaojia Ren; Jeffrey Roach; Thaís S Sabedot; Jacqueline Schein; Steven E Schumacher; Jonathan G Seidman; Sahil Seth; Hui Shen; Janae V Simons; Payal Sipahimalani; Matthew G Soloway; Xingzhi Song; Huandong Sun; Barbara Tabak; Angela Tam; Donghui Tan; Jiabin Tang; Nina Thiessen; Timothy Triche; David J Van Den Berg; Umadevi Veluvolu; Scot Waring; Daniel J Weisenberger; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Andrew W Xu; Lixing Yang; Travis I Zack; Jianhua Zhang; B Arman Aksoy; Harindra Arachchi; Chris Benz; Brady Bernard; Daniel Carlin; Juok Cho; Daniel DiCara; Scott Frazer; Gregory N Fuller; JianJiong Gao; Nils Gehlenborg; David Haussler; David I Heiman; Lisa Iype; Anders Jacobsen; Zhenlin Ju; Sol Katzman; Hoon Kim; Theo Knijnenburg; Richard Bailey Kreisberg; Michael S Lawrence; William Lee; Kalle Leinonen; Pei Lin; Shiyun Ling; Wenbin Liu; Yingchun Liu; Yuexin Liu; Yiling Lu; Gordon Mills; Sam Ng; Michael S Noble; Evan Paull; Arvind Rao; Sheila Reynolds; Gordon Saksena; Zack Sanborn; Chris Sander; Nikolaus Schultz; Yasin Senbabaoglu; Ronglai Shen; Ilya Shmulevich; Rileen Sinha; Josh Stuart; S Onur Sumer; Yichao Sun; Natalie Tasman; Barry S Taylor; Doug Voet; Nils Weinhold; John N Weinstein; Da Yang; Kosuke Yoshihara; Siyuan Zheng; Wei Zhang; Lihua Zou; Ty Abel; Sara Sadeghi; Mark L Cohen; Jenny Eschbacher; Eyas M Hattab; Aditya Raghunathan; Matthew J Schniederjan; Dina Aziz; Gene Barnett; Wendi Barrett; Darell D Bigner; Lori Boice; Cathy Brewer; Chiara Calatozzolo; Benito Campos; Carlos Gilberto Carlotti; Timothy A Chan; Lucia Cuppini; Erin Curley; Stefania Cuzzubbo; Karen Devine; Francesco DiMeco; Rebecca Duell; J Bradley Elder; Ashley Fehrenbach; Gaetano Finocchiaro; William Friedman; Jordonna Fulop; Johanna Gardner; Beth Hermes; Christel Herold-Mende; Christine Jungk; Ady Kendler; Norman L Lehman; Eric Lipp; Ouida Liu; Randy Mandt; Mary McGraw; Roger Mclendon; Christopher McPherson; Luciano Neder; Phuong Nguyen; Ardene Noss; Raffaele Nunziata; Quinn T Ostrom; Cheryl Palmer; Alessandro Perin; Bianca Pollo; Alexander Potapov; Olga Potapova; W Kimryn Rathmell; Daniil Rotin; Lisa Scarpace; Cathy Schilero; Kelly Senecal; Kristen Shimmel; Vsevolod Shurkhay; Suzanne Sifri; Rosy Singh; Andrew E Sloan; Kathy Smolenski; Susan M Staugaitis; Ruth Steele; Leigh Thorne; Daniela P C Tirapelli; Andreas Unterberg; Mahitha Vallurupalli; Yun Wang; Ronald Warnick; Felicia Williams; Yingli Wolinsky; Sue Bell; Mara Rosenberg; Chip Stewart; Franklin Huang; Jonna L Grimsby; Amie J Radenbaugh; Jianan Zhang
Journal:  N Engl J Med       Date:  2015-06-10       Impact factor: 91.245

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.

Authors:  Frank W Floeth; Dirk Pauleit; Michael Sabel; Gabriele Stoffels; Guido Reifenberger; Markus J Riemenschneider; Paul Jansen; Heinz H Coenen; Hans-Jakob Steiger; Karl-Josef Langen
Journal:  J Nucl Med       Date:  2007-04       Impact factor: 10.057

7.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

8.  Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas.

Authors:  Niklas Thon; Sabina Eigenbrod; Eva M Grasbon-Frodl; Michael Ruiter; Jan H Mehrkens; Simone Kreth; Jörg C Tonn; Hans A Kretzschmar; Friedrich W Kreth
Journal:  J Neuropathol Exp Neurol       Date:  2009-11       Impact factor: 3.685

9.  Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?

Authors:  Marcus Unterrainer; Florian Schweisthal; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Wolfgang P Fendler; Ulrich Schüller; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert
Journal:  J Nucl Med       Date:  2016-03-31       Impact factor: 10.057

10.  Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Authors:  Nathalie L Jansen; Bogdana Suchorska; Vera Wenter; Sabina Eigenbrod; Christine Schmid-Tannwald; Andreas Zwergal; Maximilian Niyazi; Mark Drexler; Peter Bartenstein; Oliver Schnell; Jörg-Christian Tonn; Niklas Thon; Friedrich-Wilhelm Kreth; Christian la Fougère
Journal:  J Nucl Med       Date:  2013-12-30       Impact factor: 10.057

View more
  27 in total

1.  Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.

Authors:  Manuel Röhrich; Kristin Huang; Daniel Schrimpf; Nathalie L Albert; Thomas Hielscher; Andreas von Deimling; Ulrich Schüller; Antonia Dimitrakopoulou-Strauss; Uwe Haberkorn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-07       Impact factor: 9.236

2.  TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative 18F-GE-180 PET study.

Authors:  M Unterrainer; D F Fleischmann; F Vettermann; V Ruf; L Kaiser; D Nelwan; S Lindner; M Brendel; V Wenter; S Stöcklein; J Herms; V M Milenkovic; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-05       Impact factor: 9.236

3.  Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Authors:  Olivia Kertels; Almuth F Kessler; Milena I Mihovilovic; Antje Stolzenburg; Thomas Linsenmann; Samuel Samnick; Stephanie Brändlein; Camelia Maria Monoranu; Ralf-Ingo Ernestus; Andreas K Buck; Mario Löhr; Constantin Lapa
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 4.  Conventional and advanced imaging throughout the cycle of care of gliomas.

Authors:  Gilles Reuter; Martin Moïse; Wolfgang Roll; Didier Martin; Arnaud Lombard; Félix Scholtes; Walter Stummer; Eric Suero Molina
Journal:  Neurosurg Rev       Date:  2021-01-07       Impact factor: 3.042

5.  Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET.

Authors:  Franziska Vettermann; Bogdana Suchorska; Marcus Unterrainer; Debie Nelwan; Robert Forbrig; Viktoria Ruf; Vera Wenter; Friedrich-Wilhelm Kreth; Jochen Herms; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-08-13       Impact factor: 9.236

6.  Comparison of [18F]Fluoroethyltyrosine PET and Sodium MRI in Cerebral Gliomas: a Pilot Study.

Authors:  Aliaksandra Shymanskaya; Wieland A Worthoff; Gabriele Stoffels; Johannes Lindemeyer; Bernd Neumaier; Philipp Lohmann; Norbert Galldiks; Karl-Josef Langen; N Jon Shah
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

7.  Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.

Authors:  M Unterrainer; I Winkelmann; B Suchorska; A Giese; V Wenter; F W Kreth; J Herms; P Bartenstein; J C Tonn; N L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-27       Impact factor: 9.236

8.  Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.

Authors:  Mathias Kunz; Nathalie Lisa Albert; Marcus Unterrainer; Christian la Fougere; Rupert Egensperger; Ulrich Schüller; Juergen Lutz; Simone Kreth; Jörg-Christian Tonn; Friedrich-Wilhelm Kreth; Niklas Thon
Journal:  Neuro Oncol       Date:  2019-02-14       Impact factor: 12.300

9.  Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study.

Authors:  Marcus Unterrainer; D F Fleischmann; C Diekmann; L Vomacka; S Lindner; F Vettermann; M Brendel; V Wenter; B Ertl-Wagner; J Herms; C Wetzel; R Rupprecht; J C Tonn; C Belka; P Bartenstein; M Niyazi; Nathalie L Albert
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-22       Impact factor: 9.236

10.  Integration of dynamic parameters in the analysis of 18F-FDopa PET imaging improves the prediction of molecular features of gliomas.

Authors:  Merwan Ginet; Timothée Zaragori; Pierre-Yves Marie; Véronique Roch; Guillaume Gauchotte; Fabien Rech; Marie Blonski; Zohra Lamiral; Luc Taillandier; Laëtitia Imbert; Antoine Verger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-16       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.